^
Association details:
Evidence:
Evidence Level:
Sensitive: A1 - Approval
New
Source:
Title:

Accord BioPharma, Inc. Announces U.S. Food & Drug Administration Approval of 420mg Strength of HERCESSI™ (trastuzumab-strf), a biosimilar to Herceptin® (trastuzumab), for the Treatment of Several Forms of HER2-Overexpressing Cancer

Published date:
09/18/2024
Excerpt:
...the U.S. Food and Drug Administration (FDA) has approved a 420mg strength of HERCESSI™ (trastuzumab-strf), a biosimilar to Herceptin® (trastuzumab), to treat HER2-overexpressing breast and gastric or gastroesophageal junction adenocarcinoma.
Evidence Level:
Sensitive: A1 - Approval
Published date:
07/27/2020
Excerpt:
Zercepac should only be used in patients with metastatic gastric cancer (MGC) whose tumours have HER2 overexpression…